O emprego da proloterapia nas disfunções temporomandibulares
The use of prolotherapy in temporomandibular disorders
Eduardo Grossmann; Rodrigo Lorenzi Poluha
Resumo
Palavras-chave
Abstract
BACKGROUND AND OBJECTIVES: The search for minimally invasive treatments for temporomandibular disorders (TMD) has increased in recent years. Prolotherapy, which uses irritant solutions to induce controlled inflammation and tissue regeneration, has emerged as a promising alternative. This article reviews its mechanisms of action, indications, contraindications, application formulas, and clinical outcomes.
CONTENTS: In recent years, research has focused on clinical and minimally invasive treatments for TMD, as well as on determining when and how to apply them effectively. Prolotherapy stands out as a minimally invasive approach that is cost-effective, performed under local anesthesia, replicable, and associated with low morbidity. Its application aims to relieve or eliminate pain and joint dysfunction, making it a promising option in such cases.
CONCLUSION: Prolotherapy, based on the use of dextrose in varying concentrations, has shown encouraging results in the treatment of Temporomandibular Disorders (TMD), particularly in cases of myofascial pain, joint hypermobility, and disc displacement with reduction. By promoting tissue regeneration and stabilizing the temporomandibular joint (TMJ), this technique offers a less invasive alternative with long-lasting results. However, further studies are essential to standardize treatment protocols and to explore its specific indications and contraindications in more detail.
Keywords
Referências
1 Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, List T, Svensson P, Gonzalez Y, Lobbezoo F, Michelotti A, Brooks SL, Ceusters W, Drangsholt M, Ettlin D, Gaul C, Goldberg LJ, Haythornthwaite JA, Hollender L, Jensen R, John MT, De Laat A, de Leeuw R, Maixner W, van der Meulen M, Murray GM, Nixdorf DR, Palla S, Petersson A, Pionchon P, Smith B, Visscher CM, Zakrzewska J, Dworkin SF, International RDC/TMD Consortium Network, International association for Dental Research, Orofacial Pain Special Interest Group, International Association for the Study of Pain. International RDC/TMD Consortium Network, International association for Dental Research; Orofacial Pain Special Interest Group, International Association for the Study of Pain. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. J Oral Facial Pain Headache. 2014;28(1):6-27.
2 Fernandes G, Gonçalves DAG, Conti P. Musculoskeletal Disorders. Dent Clin North Am. 2018;62(4):553-64.
3 Liu F, Steinkeler A. Epidemiology, diagnosis, and treatment of temporomandibular disorders. Dent Clin North Am. 2013;57(3):465-79.
4 Dimitroulis G. Management of temporomandibular joint disorders: a surgeon’s perspective. Aust Dent J. 2018;63(Suppl 1):S79-90.
5 Hakala RV. Prolotherapy (proliferationtherapy) in the treatment of TMD. Cranio. 2005;23(4):283-8.
6 Goswami A. Prolotherapy. J Pain Palliat Care Pharmacother. 2012;26(4):376-8.
7 Hackett GS, Hemwall G, Montgomery G. Ligament and tendon relaxation treated by prolotherapy. 5th ed. Oak Park: Gustav A. Hemwall MD; 1993.
8 Hackett GS. Ligament and tendon relaxation treated by prolotherapy. Springfield: Charles C Thomas; 1956.
9 Andre A, Kang J, Dym H. Pharmacologic treatment for temporomandibular and temporomandibular joint disorders. Oral Maxillofac Surg Clin North Am. 2022;34(1):49-59.
10 Majumdar SK, Krishna S, Chatterjee A, Chakraborty R, Ansari N. Single injection technique prolotherapy for hypermobility disorders of TMJ using 25% dextrose: a clinical study. J Maxillofac Oral Surg. 2017;16(2):226-30.
11 Ravikumar C, Sasikala B, Krishnakumar Raja VB, Elavenil P. Evaluation of the efficacy of autologous conditioned serum versus dextrose prolotherapy in internal derangement of the TMJ - A pilot study. J Craniomaxillofac Surg. 2024;52(4):477-83.
12 Kim MY, Na YM, Moon JH. Comparison on treatment effects of dextrose water, saline, and lidocaine for trigger point injections. J Korean Acad Rehabil Med. 1997;21:967-73.
13 Hakala RV, Lederman KM. The use of prolotherapy for temporomandibular joint dysfunction. J of Prolotherapy. 2010;2(3):439-46.
14 Gibaly A, Abdelmoiz M, Alghandour AN. Evaluation of the effect of dextrose prolotherapy versus deep dry needling therapy for the treatment of temporomandibular joint anterior disc displacement with reduction: (a randomized controlled trial). Clin Oral Investig. 2024;28(9):475.
15 Zhou H, Hu K, Ding Y. Modified dextrose prolotherapy for recurrent temporomandibular joint dislocation. Br J Oral Maxillofac Surg. 2014;52(1):63-6.
16 Cömert Kiliç S, Güngörmüş M. Is dextrose prolotherapy superior to placebo for the treatment of temporomandibular joint hypermobility? A randomized clinical trial. Int J Oral Maxillofac Surg. 2016;45(7):813-9.
17 Mustafa R, Güngörmüş M, Mollaoğlu N. Evaluation of the efficacy of different concentrations of dextrose prolotherapy in temporomandibular joint hypermobility treatment. J Craniofac Surg. 2018;29(5):e461-5.
18 Lee W. Prolotherapy of the temporomandibular joint is denoted as a new health technology in Korea. J Korean Assoc Oral Maxillofac Surg. 2023;49(2):59-60.
19 Cömert Kiliç S, Kiliç N, Güngörmüş M. Botulinum toxin versus dextrose prolotherapy: which is more effective for temporomandibular joint subluxation? A Randomized Clinical Trial. J Oral Maxillofac Surg. 2023;81(4):389-95.
20 Singh V, Trescot A, Nishio I. Injections for chronic pain. Phys Med Rehabil Clin N Am. 2015;26(2):249-61.
21 Refai H, Altahhan O, Elsharkawy R. The efficacy of dextrose prolotherapy for temporomandibular joint hypermobility: a preliminary prospective, randomized, double-blind, placebo controlled clinical trial. J Oral Maxillofac Surg. 2011;69(12):2962-70.
22 Grossmann E, Poluha RL. Double-puncture versus single-puncture arthrocentesis: a randomized controlled trial with 3 years of follow-up. J Oral Facial Pain Headache. 2022;36(2):141-6.
23 Grossmann E, Poluha RL. b Comparative study of arthrocentesis with concentric-needle cannula with classic concentric needle: a randomized single-blind controlled clinical trial. J Craniomaxillofac Surg. 2024;52(7):850-4.
24 Grossmann E, Poluha RL. Comparison between TMJ arthrocentesis techniques with different needle positions: a randomized single-blind controlled clinical trial. J Craniomaxillofac Surg. 2021;49(5):368-72.
25 Grossmann E, Poluha RL. The benefits of performing temporomandibular joint arthrocentesis with catheters and a vacuum pump: a randomized control trial. J Craniomaxillofac Surg. 2024;52(3):369-73.
26 Priyadarshini S, Gnanam A, Sasikala B, Elavenil P, Raja Sethupathy Cheeman S, Mrunalini R, Krishna Kumar Raja VB. Evaluation of prolotherapy in comparison with occlusal splints in treating internal derangement of the temporomandibular joint - A randomized controlled trial. J Craniomaxillofac Surg. 2021;49(1):24-8.
27 Renapurkar SK, Laskin DM. Injectable agents versus surgery for recurrent temporomandibular joint dislocation. Oral Maxillofac Surg Clin North Am. 2018;30(3):343-9.
28 Prechel U, Ottl P, Ahlers OM, Neff A. The treatment of temporomandibular joint dislocation. Dtsch Arztebl Int. 2018;115(5):59-64. PMid:29439762.
29 Vingender S, Dőri F, Schmidt P, Hermann P, Vaszilkó MT. Evaluation of the efficiency of hyaluronic acid, PRP and I-PRF intra-articular injections in the treatment of internal derangement of the temporomandibular joint: a prospective study. J Craniomaxillofac Surg. 2023;51(1):1-6.
30 Al-Moraissi EA, Wolford LM, Ellis E 3rd, Neff A. The hierarchy of different treatments for arthrogenous temporomandibular disorders: a network meta-analysis of randomized clinical trials. J Craniomaxillofac Surg. 2020;48(1):9-23.
31 Poluha RL, Canales GT, Costa YM, Grossmann E, Bonjardim LR, Conti PCR. Temporomandibular joint disc displacement with reduction: a review of mechanisms and clinical presentation. J Appl Oral Sci. 2019;27:e2019er001. http://doi.org/10.1590/1678-7757-2018-0433. PMid:30810641.
32 Nitzan DW, Naaman HL. Athrocentesis: what, when, and why? Atlas Oral Maxillofac Surg Clin North Am. 2022;30(2):137-45.
33 George MD, Lee RJ, Kryscio RJ, Kaplan JD. Safety and efficacy of prolotherapy in the management of temporomandibular joint disorders. J Maxillofac Oral Surg. 2015;14(1):49-56.
34 Haggag MA, Al-Belasy FA, Said Ahmed WM. Dextrose prolotherapy for pain and dysfunction of the TMJ reducible disc displacement: A randomized, double-blind clinical study. J Craniomaxillofac Surg. 2022;50(5):426-31.
35 Haggag MH, El-Saeed TA, Shabana TM. Efficacy of dextrose prolotherapy compared with lidocaine injection in temporomandibular joint disorders: a randomized clinical trial. J Oral Maxillofac Surg. 2017;75(5):946-52.
36 Haggag MH, El-Saeed TA, Shabana TM. Prolotherapy: a new approach for temporomandibular joint dysfunction. Egypt Dent J. 2020;66(3):2735-42.
37 Haggag MH, El-Saeed TA, Shabana TM. Long-term outcomes of prolotherapy in temporomandibular joint dysfunction. J Oral Maxillofac Surg. 2017;75(6):954-60.
38 Hauser RA, Hauser MA, Baird NM. Evidence-based use of dextrose prolotherapy for musculoskeletal pain: a review. Clin Med Insights Arthritis Musculoskelet Disord. 2016;9:139-59.
39 Hauser RA, Hauser MA. Dextrose prolotherapy for degenerative joint disease of the temporomandibular joint: a prospective pilot study. J Prolotherapy. 2009;1(3):167-75.
40 Hsu C, Vu K, Borg-Stein J. Prolotherapy: a narrative review of mechanisms, techniques, and protocols, and evidence for common musculoskeletal conditions. Phys Med Rehabil Clin N Am. 2023;34(1):165-80.
41 Dasukil S, Shetty SK, Arora G, Degala S. Efficacy of prolotherapy in temporomandibular joint disorders: an exploratory study. J Maxillofac Oral Surg. 2021;20(1):115-20.
42 ELwerfelli AM, Kalil AEF, Abdullah NS. Clinical evaluation of dextrose prolotherapy for management of temporomandibular joint disorder. Alex Dent J. 2019;4(3):1-7.
43 Mohammed MM, Abdelkarim FM. Prolotherapy compared to corticosteroid in the treatment of temporomandibular joint pain: a clinical trial. Pain Res Manag. 2019;6:123-31.
44 Zarate P, Martinez JE, Padilla NR. Prolotherapy for temporomandibular joint hypermobility: a clinical update. J Oral Rehabil. 2023;50(7):792-8.
45 Fouda AA. Change of site of intra-articular injection of hypertonic dextrose resulted in different effects of treatment. Br J Oral Maxillofac Surg. 2018;56(8):715-8.
46 Zarate P, Martinez JE, Padilla NR. Prolotherapy in temporomandibular joint hypermobility: a review of the literature. J Prolotherapy. 2010;2(2):448-52.
47 Sit RW, Chung VC, Reeves KD, Rabago DP. The effectiveness of prolotherapy for temporomandibular joint disorders: A systematic review and meta-analysis. Pain Physician. 2022;25(3):361-70.
48 Rahimzadeh P, Imani F, Faiz SH, Pourhoseingholi MA. Dextrose prolotherapy vs local anesthetic injection for the treatment of temporomandibular joint hypermobility: a randomized clinical trial. Pain Pract. 2014;14(7):641-5.
49 Jacob SM, Bandyopadhyay TK, Chattopadhyay PK, Parihar VS. Efficacy of platelet-rich plasma versus hyaluronic acid following arthrocentesis for temporomandibular joint disc disorders: a randomized controlled trial. J Maxillofac Oral Surg. 2022;21(4):1199-204.
50 Rossini R, Grossmann E, Poluha RL, Setogutti ÊT, Dos Santos MF. Double-needle arthrocentesis with viscosupplementation in patients with temporomandibular joint disc displacement without reduction. Clinics (São Paulo). 2021;76:e2840.
51 Wang R, Bi R, Liu Y, Cao P, Abotaleb B, Zhu S. Morphological changes of TMJ disc in surgically treated ADDwoR patients: a retrospective study. BMC Oral Health. 2022;22(1):432.
52 Wroclawski C, Mediratta JK, Fillmore WJ. Recent Advances in Temporomandibular Joint Surgery. Medicina (Kaunas). 2023;59(8):1409.
53 De Nordenflycht D, Ayala A, Orellana L, Tesch RS. Intra-articular injections in the TMJ inferior joint space: A scoping review. J Oral Rehabil. 2023;50(11):1316-29.
54 Ling LP, Lua JL, Tang JS. The effect of dextrose prolotherapy on temporomandibular joint hypermobility: A prospective randomized clinical trial. J Oral Maxillofac Surg. 2013;71(12):2177-84.
55 Zarate P, Martinez JE, Padilla NR. Prolotherapy versus lidocaine injection for temporomandibular joint disorders: a randomized controlled trial. J Oral Rehabil. 2022;49(6):726-32.
56 Bhargava D, Sivakumar B, Bhargava PG. A Comparative Preliminary Randomized Clinical Study to Evaluate Heavy Bupivacaine Dextrose Prolotherapy (HDP) and Autologous Blood Injection (ABI) for Symptomatic Temporomandibular Joint Hypermobility Disorder. J Maxillofac Oral Surg. 2023;22(1):110-8.
57 Long X, Chen G, Cheng AH, Cheng Y, Deng M, Cai H, Meng Q. A randomized controlled trial of superior and inferior temporomandibular joint space injection with hyaluronic acid in treatment of anterior disc displacement without reduction. J Oral Maxillofac Surg. 2009;67(2):357-61.
58 Reeves KD, Sit RW, Rabago DP. Prolotherapy: a non-surgical option for managing temporomandibular joint disorders. Pain Pract. 2021;21(2):123-32.
59 Tocaciu S, McCullough MJ, Dimitroulis G. Surgical management of recurrent TMJ dislocation-a systematic review. Oral Maxillofac Surg. 2019;23(1):35-45.
60 Rabago D, Best TM, Beamsley M, Patterson J. A systematic review of prolotherapy for chronic musculoskeletal pain. Clin J Sport Med. 2005;15(5):376-80.
61 Reeves KD, Hassanein KM. Long-term effects of dextrose prolotherapy for anterior cruciate ligament laxity. Altern Ther Health Med. 2003;9(3):58-62. PMid:12776476.
62 Sit RW, Reeves KD, Zhong CC, Wong CHL, Wang B, Chung VC, Wong SY, Rabago D. Efficacy of hypertonic dextrose injection (prolotherapy) in temporomandibular joint dysfunction: a systematic review and meta-analysis. Sci Rep. 2021;11(1):14638.
Submetido em:
12/11/2024
Aceito em:
25/02/2025
Facebook
Google+
Twitter
LinkedIn
Mendeley
Email